Form 4: Niagen Bioscience CEO Exercises Stock Options Ahead of Expiration

Robert N. Fried, CEO of Niagen Bioscience, exercised stock options for 66,667 shares of common stock at $3.3 per share on April 9, 2025.

Summary

• On April 9, 2025, Robert N. Fried, the CEO of Niagen Bioscience, exercised stock options to acquire 66,667 shares of common stock at a price of $3.3 per share.
• The options were exercised in advance of their expiration date of July 29, 2025.
• Following the transaction, Fried directly owns 1,038,981 shares of Niagen Bioscience common stock.
• Fried also has indirect ownership through various trusts, including the Fried-Travis Revocable Trust, The Jeremy W Fried 2020 Irrevocable Trust, and The Benjamin A Fried 2020 Irrevocable Trust.
• He disclaims beneficial ownership of the shares held by The Jeremy W Fried 2020 Irrevocable Trust and The Benjamin A Fried 2020 Irrevocable Trust.
• Additionally, 12,746 shares are held by his sons, Jeremy Fried and Benjamin Fried.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock option exercises, which is neither particularly positive nor negative. It's a neutral disclosure of insider transactions.

Positives

• The CEO's decision to exercise options and increase his direct shareholding could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The exercise of stock options is a common occurrence and doesn't necessarily indicate a significant shift in the company's outlook.

Comparison to Industry Standards

• Comparing the CEO's ownership stake and option exercises to those of executives at similar-sized biotech companies would provide a better understanding of whether this transaction is typical.
• For example, CEOs at comparable companies like ChromaDex or Elysium Health may have similar compensation structures involving stock options and restricted stock units.
• Analyzing the vesting schedules and exercise prices of these options relative to the company's stock performance can offer insights into the alignment of management's interests with those of shareholders.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly diluting the existing shares, but the effect is likely minimal given the size of the transaction relative to the company's overall capitalization.

Key Dates

Keywords

Niagen Bioscience, Robert Fried, Stock Options, Beneficial Ownership, Form 4, CEO, Securities